PDCD1 and melanoma: In a phase III clinical trial of anti-Lag-3 (relatlimab, 160 mg Q4W) combined with nivolumab (480 mg Q4W) for melanoma patients, patients receiving dual Lag-3/PD-1 blockade showed an increased PFS than those receiving nivolumab alone (median PFS 10.1 months vs 4.63 months, and PFS rates 47.7% vs 36.0% at 12 months).